Genzyme's Winning Combination
S&P likes the biotech leader's product pipeline and top-flight management. And its new dialysis product is a potential blockbuster
By Frank DiLorenzo
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: